Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
Open Access
- 20 September 2021
- journal article
- review article
- Published by Elsevier in Genes & Diseases
- Vol. 9 (5) , 1181-1193
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research Institute
- National Institutes of Health (R01CA175495, R01DK100525)
- U.S. Department of War (BC190403)
This publication has 154 references indexed in Scilit:
- B7x and myeloid-derived suppressor cells in the tumor microenvironmentOncoImmunology, 2013
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 familyImmunological Reviews, 2011
- Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell CarcinomaClinical Cancer Research, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survivalProceedings of the National Academy of Sciences, 2006
- B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinomaJournal of Experimental Medicine, 2006
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLOS Medicine, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004